Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study

Abstract

R788-1301 (NCT04132050) is a phase 3, multicenter, randomized, parallel-group study of fostamatinib, an oral spleen tyrosine kinase inhibitor, in Japanese patients with primary ITP. 1 The study consists of four parts: a placebo-controlled, double-blind study of fostamatinib for 24 weeks (Period I), an open-label study of fostamatinib for 28 weeks (Period II), a washout period of up to 4 weeks, and an open-